ArticleBMC cancer2008
Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.
Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.BMC cancer · 2018Pooled it
- Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies.PloS one · 2013Pooled it
- New Oxicam Derivatives-Studies of Membrane Interactions, Cytotoxicity, Cyclooxygenase Inhibition and Molecular Docking.Membranes · 2026Article
- The Role of Prostaglandins as Major Inflammatory Mediators in Colorectal Cancer.International journal of molecular sciences · 2025Review
- Harnessing Oxylipins and Inflammation Modulation for Prevention and Treatment of Colorectal Cancer.International journal of molecular sciences · 2024Review
- Janus Dendrimers as Nanocarriers of Ibuprofen, Chlorambucil and their Anticancer Activity.Pharmaceutical nanotechnology · 2024Article
- Aspirin and nonaspirin nonsteroidal antiinflammatory drug use and occurrence of colorectal adenoma in Black American women.International journal of cancer · 2023Article
- Review
- Overview of Prostaglandin E2 (PGE2)-Targeting Radiolabelled Imaging Probes from Preclinical Perspective: Lessons Learned and Road Ahead.International journal of molecular sciences · 2023Review
- Preventive effects of 13 different drugs on colorectal cancer: a network meta-analysis.Archives of medical science : AMS · 2023Review
- Effects of Cyclooxygenase-2 Inhibitors on Gastrointestinal Malignancies: a Systematic Review and Meta-analysis.Indian journal of surgical oncology · 2022Article
- Iron: An Essential Element of Cancer Metabolism.Cells · 2020Review
- Chemoprevention of Colorectal Cancer.Gastroenterology · 2020Review
- Interaction between Nonsteroidal Anti-inflammatory Drugs and Low-fat Dietary Intervention on Colorectal Cancer Incidence; the Women's Health Initiative (WHI) Dietary Modification Trial.Journal of the American College of Nutrition · 2017Article
- Use of acetaminophen in relation to the occurrence of cancer: a review of epidemiologic studies.Cancer causes & control : CCC · 2016Review
- Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH-naproxen (AVT-219) a dual NO- and H2S-releasing hybrid.Pharmacology research & perspectives · 2016Article
- COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells.Medicine · 2015Observational
- Cyclooxygenase-2 and the inflammogenesis of breast cancer.World journal of clinical oncology · 2014Review
- Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2014Article
- Indomethacin inhibits cancer cell migration via attenuation of cellular calcium mobilization.Molecules (Basel, Switzerland) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundEpidemiologic and laboratory investigations suggest that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have chemopreventive effects against colon cancer perhaps due at least in part to their activity against cyclooxygenase-2 (COX-2), the rate-limiting enzyme of the prostaglandin cascade.
methodsWe conducted a case control study of colon cancer designed to compare effects of selective and non-selective COX-2 inhibitors. A total of 326 incident colon cancer patients were ascertained from the James Cancer Hospital, Columbus, Ohio, during 2003-2004 and compared with 652 controls with no history of cancer and matched to the cases at a 2:1 ratio on age, race, and county of residence. Data on the past and current use of prescription and over the counter medications and colon cancer risk factors were ascertained using a standardized risk factor questionnaire. Effects of COX-2 inhibiting agents were quantified by calculating odds ratios (OR) and 95% confidence intervals.
resultsResults showed significant risk reductions for selective COX-2 inhibitors (OR = 0.31, 95% CI = 0.16-0.57), regular aspirin (OR = 0.33, 95% CI = 0.20-0.56), and ibuprofen or naproxen (0.28, 95% CI = 0.15-0.54). Acetaminophen, a compound with negligible COX-2 activity and low dose aspirin (81 mg) produced no significant change in the risk of colon cancer.
conclusionThese results suggest that both non-selective and selective COX-2 inhibitors produce significant reductions in the risk of colon cancer, underscoring their strong potential for colon cancer chemoprevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.